Cantel Medical

Cantel Medical Corp. (NYSE:CMN) is a leading provider of infection prevention and control products in the healthcare market. Their products include water purification equipment, sterilants, disinfectants and cleaners, specialized medical device reprocessing systems for endoscopy and renal dialysis, disposable infection control products primarily for dental and GI endoscopy markets, dialysate concentrates and other dialysis supplies, hollow fiber membrane filtration and separation products for medical and non-medical applications, and specialty packaging for infectious and biological specimens. They also provide technical maintenance for their products and offer compliance training services for the transport of infectious and biological specimens.

Cantel Medical Corp. engages in the development and manufacture of infection prevention products and services in the healthcare market. It operates through the following business segments: Medical, Life Sciences, Dental and Dialysis. The Medical segment designs, develops, manufactures, sells and installs a comprehensive products and services comprising a complete circle of infection prevention solutions. The Life Sciences segment designs, develops, manufactures, sells and installs water purification systems for medical, pharmaceutical and other bacteria controlled applications. The Dental segment designs, manufactures, sells, supplies and distributes single-use infection prevention healthcare products, used by dental practitioners. The Dialysis segment designs, develops, manufactures, and sells reprocessing systems for dialyzers. Cantel Medical was founded on August 16, 1963 and is headquartered in Little Falls, NJ.

S&P Global

STERIS

NEW YORK, May 26, 2021 /PRNewswire/ -- S&P SmallCap 600 constituent Crocs Inc. (NASD:CROX) will replace Cantel Medical Corp. (NYSE:CMD) in the S&P MidCap 400, and Organogenesis Holdings Inc. (NASD: ORGO) will replace Crocs in the S&P SmallCap 600 effective prior to the opening of trading on Wednesday, June 2, 2021. STERIS plc (NYSE: STE) is acquiring Cantel Medical in a deal expected to be completed soon pending final closing conditions.

Crocs Set to Join S&P MidCap 400 and Organogenesis to Join S&P SmallCap 600

PLYMOUTH, Minn.--(BUSINESS WIRE)-- #Hemodialysis--Mar Cor launches the EON Portable RO Dialysis Water System. It produces high-quality medical water for acute and home hemodialysis use.

Mar Cor Launches Its Newest and Most Advanced Portable Reverse Osmosis Water System

Cantel (CMD) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Cantel (CMD) Hits 52-Week High, Can the Run Continue?

Hill-Rom Hlds

LeMaitre Vascular

Masimo

Cantel (CMD), Hill-Rom (HRC), LeMaitre (LMAT) and Masimo (MASI) can prove to be prudent investment choices in the critical care industry of the MedTech sector.

4 Critical Care Device Stocks to Deflect the COVID-19 Curveball

Cantel (CMD) possesses solid growth attributes, which could help it handily outperform the market.

Is Cantel (CMD) a Solid Growth Stock? 3 Reasons to Think " Yes "

Cantel (CMD) could produce exceptional returns because of its solid growth attributes.

Looking for a Growth Stock? 3 Reasons Why Cantel (CMD) is a Solid Choice

Coherent Corp

Lionheart Holdings

Pandion Therapeutics Holdco LLC

Perspecta Inc

NEW YORK, March 11, 2021 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: Cantel Medical Corp. (NYSE: CMD) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to STERIS plc for approximately $16.93 in cash and 0.33787 STERIS ordinary shares for each Cantel common share. If you are a Cantel shareholder, click here to learn more about your rights and options.

INVESTIGATION ALERT: Halper Sadeh LLP Investigates CMD, COHR, PRSP, CUB, PAND; Shareholders are Encouraged to Contact the Firm

ABIOMED

CMD vs. ABMD: Which Stock Is the Better Value Option?

CMD or ABMD: Which Is the Better Value Stock Right Now?

Cantel (CMD) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

What Makes Cantel (CMD) a New Buy Stock

Cantel Medical Corp. (CMD) CEO George Fotiades on Q2 2021 Results - Earnings Call Transcript

Cantel (CMD) delivered earnings and revenue surprises of 61.22% and 9.39%, respectively, for the quarter ended January 2021. Do the numbers hold clues to what lies ahead for the stock?

Cantel Medical (CMD) Q2 Earnings and Revenues Top Estimates

LITTLE FALLS, N.J., March 9, 2021 /PRNewswire/ -- Cantel Medical Corp. (NYSE: CMD) today announced financial results for its second quarter ended January 31, 2021.

Cantel Medical Reports Strong Financial Results for its Second Quarter Fiscal Year 2021

Cantel Medical (NYSE:CMD) announces its next round of earnings this Tuesday, March 09. Here is Benzinga's everything-that-matters guide for this Tuesday's Q2 earnings announcement.

Earnings Outlook for Cantel Medical

Cantel (CMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate Cantel Medical (CMD) to Report a Decline in Earnings: What to Look Out for

LITTLE FALLS, N.J., Feb. 25, 2021 /PRNewswire/ -- CANTEL MEDICAL CORP. (NYSE:CMD) will release the results for its second quarter ended January 31, 2021 on Tuesday, March 9, 2021 before the market opens, and hold a conference call to discuss the results at 8:30 a.m. ET. To participate in...

Cantel Medical Corp. to Hold Conference Call to Discuss Results for its Second Quarter Ended January 31, 2021

NEW ORLEANS, Feb. 9, 2021 /PRNewswire/ -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ("KSF") are investigating the proposed sale of Cantel Medical Corp (NYSE: CMD) to STERIS plc (NYSE: STE). Under the terms of the proposed...

CANTEL MEDICAL INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Cantel Medical Corp - CMD

WILMINGTON, Del., Jan. 13, 2021 (GLOBE NEWSWIRE) -- Rigrodsky Law, P.A. announces that it is investigating Cantel Medical Corp. (“Cantel”) (NYSE: CMD) regarding possible breaches of fiduciary duties and other violations of law related to Cantel's agreement to be acquired by STERIS plc (“STERIS”) (NYSE: STE). Under the terms of the agreement, Cantel's shareholders will receive approximately $16.93 in cash and 0.33787 of a share of STERIS per share.

SHAREHOLDER ALERT: Rigrodsky Law, P.A. Announces Investigation of Cantel Medical Corp. Buyout

NEW YORK, Jan. 13, 2021 /PRNewswire/ -- Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in New York City, is investigating Cantel Medical Corp. ("CMD" or the "Company") (CMD) relating to its...

SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Cantel Medical Corp. - CMD

Does Cantel Medical (CMD) have what it takes to be a top stock pick for momentum investors? Let's find out.

Cantel Medical (CMD) is a Great Momentum Stock: Should You Buy?

STERIS (STE) expects to strengthen and expand its endoscopy offerings along with extending into a new customer territory via the Cantel Medical buyout.

STERIS (STE) to Expand Product Suite Via Cantel Medical Buyout

NEW YORK, Jan. 13, 2021 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: Cantel Medical Corp. (NYSE: CMD) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating...

SHAREHOLDER ALERT: Halper Sadeh LLP Investigates CMD, TCF, ALSK, SMTX, ZAGG; Shareholders Are Encouraged to Contact the Firm

NEW YORK, Jan. 12, 2021 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Cantel Medical Corp. ("CMD" or the "Company") (NYSE: CMD) in connection with the proposed acquisition of the Company by STERIS...

SHAREHOLDER ALERT: WeissLaw LLP Investigates Cantel Medical Corp.

NEW YORK, Jan. 12, 2021 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by Cantel Medical Corporation (NYSE: CMD) ("Cantel") and its board of directors concerning the proposed acquisition of the company by Steris Plc (NYSE: STE) ("Steris"). Under the...

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Cantel Medical Corporation

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, a global investor rights law firm, is investigating whether Cantel Medical Corp. (NYSE: CMD) and its board of directors violated the federal securities laws and/or breached their fiduciary duties to shareholders in connection with the proposed sale of Cantel to STERIS plc. Under the terms of the merger agreement, Cantel shareholders will receive approximately $16.93 in cash and 0.33787 of a STERIS ordinary share per Cantel common share. On behalf of

Cantel Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Sale of Cantel Medical Corp. Is Fair to Shareholders; Investors Are Encouraged to Contact the Firm – CMD

Shares of Cantel Medical Corp. rose 1.8% in premarket trading Tuesday, after the infection prevention products company announced an agreement to be acquired by Ireland-based Steris PLC in a cash and equity deal valued at $4.6 billion, including debt. Steris shares fell 1.2%.

News for Cantel Medical Stock (CMD)